ASCO 2026 | TrioMBM: relatlimab, nivolumab, and ipilimumab in melanoma brain metastases
Allison Betof Warner, MD, Stanford University, Stanford, CA, describes the Phase II TrioMBM trial (NCT06712927) of triplet immune checkpoint blockade with relatlimab, nivolumab, and ipilimumab in patients with asymptomatic and symptomatic melanoma brain metastases (MBM). The study enrolls two cohorts based on symptom status, with the primary endpoint of intracranial benefit rate, aiming to improve outcomes beyond current dual checkpoint inhibitor standards of care in this challenging population. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
TRIO MBM is an ongoing, open, and enrolling, investigator-initiated study looking at the combination of ipilimumab, nivolumab, and relatlimab for first-line treatment of patients with melanoma brain metastasis. We know that there’s a huge challenge in our field. Thirty-ish percent of patients will be diagnosed with brain metastasis at the time of diagnosis of metastatic disease...
TRIO MBM is an ongoing, open, and enrolling, investigator-initiated study looking at the combination of ipilimumab, nivolumab, and relatlimab for first-line treatment of patients with melanoma brain metastasis. We know that there’s a huge challenge in our field. Thirty-ish percent of patients will be diagnosed with brain metastasis at the time of diagnosis of metastatic disease. And up to 70% of our patients who die of melanoma have brain metastases. And unfortunately, these patients are basically excluded from every clinical trial that we run. And so this is a clinical trial dedicated to those patients. They get the triplet combination. And we are comparing that against historical comparators of the use of ipilimumab plus nivolumab from Checkmate 204.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
